Morphic Holding, Inc.

Morphic Holding, Inc.

MORF
Morphic Holding, Inc.US flagNASDAQ Global Market
56.99
USD
+0.02
- -
2.86BMarket Cap
Morphic Holding, Inc.
MORF
(NASDAQ Global Market)

Recent

price

56.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
0.15
1.05
1.47
0.55
1.86
0.01
- -
Revenue per Share
-1.27
-1.04
-2.69
-1.47
-2.67
-1.55
-3.59
-3.6
Basic EPS, GAAP
-1.23
3.31
-2.72
-1.52
-2.36
-2.66
-2.68
-2.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.28
-2.37
-6.06
-4.66
-6.65
-7.8
-10.6
-11.07
Book Value per Share
-2.23
-2.3
8.75
4.75
9.41
9.16
16.44
12.4
Tangible Book Value per Share
13
23
16
31
36
38
42
50
Basic Weighted Avg Shares
- -
3
17
45
20
71
1
- -
Sales/Revenue/Turnover
- -
-733.41
-276.77
-104.97
-484.02
-89.53
-34,296.74
- -
Operating Margin (%)
- -
1
1
1
1
1
1
1
Depreciation Expense
-17
-24
-43
-45
-96
-59
-152
-180
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-709.68
-255.22
-100.12
-482.68
-83.38
-29,192.9
- -
Profit Margin (%)
19
152
208
200
380
345
692
613
Working Capital
- -
- -
- -
- -
4
2
1
1
LT Debt
-30
-53
141
145
337
349
697
618
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
1,271
1,665
1,700

Working Capital

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
717
676
639
Cash, Cash Equivalents & STI
704
659
628
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
25
18
27
Payables & Accruals
23
16
24
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-25.98%
99.65%
Free Cash Flow
- -
-7.62%
12.05%
Net Income, GAAP
- -
63.48%
157.61%
Sales/Revenue/Turnover
- -
134.56%
-99.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
2
60
2
6
71
2023
1
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.85
0.7
-0.78
- -
-1.55
2023
-0.9
-0.92
-0.73
- -
-3.59
2024
-0.91
-1.15
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Morphic Holding, Inc. (MORF) is a biopharmaceutical company that discovers and develops oral small-molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune conditions such as inflammatory bowel disease (IBD), cardiovascular and metabolic diseases, fibrosis, and cancer; its lead product candidate, MORF-057, is a selective oral α4β7 integrin inhibitor currently advancing in two Phase 2 clinical studies for ulcerative colitis and one Phase 2 study for Crohn's disease; additional pipeline candidates leverage the proprietary MInT (Morphic Integrin Technology) Platform, which enables targeting of all 24 human integrin types with inhibitors and activators derived from a library exceeding 16,000 unique compounds. The company utilizes its expertise in integrin biology, structural analysis, and therapeutic design to address limitations of prior intravenous or topical integrin therapies, focusing on patient populations with unmet needs in gastroenterology, immunology, and beyond. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic Holding operates primarily in the United States with a global development footprint for its clinical programs. In 2024, Eli Lilly and Company completed its $3.2 billion acquisition of Morphic Holding at $57 per share through a tender offer and subsequent merger, integrating Morphic as a wholly owned subsidiary to bolster Lilly's immunology portfolio with oral integrin therapies for IBD and other indications.

Company News

APIChat
  • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

  • Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

  • MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!

  • MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

  • Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

  • MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

  • MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

  • MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

  • MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

  • Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

  • MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

  • MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

  • MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California

  • MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

  • Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!

  • Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!